CBCI Society for Medical Education

Their core work

CBCI Society for Medical Education is a medical education and healthcare institution based in Koramangala, India, contributing clinical and community health expertise to international research consortia. Their work spans vaccine delivery research, pandemic preparedness, and preventive oncology, with particular strength in population-based studies conducted in low-resource and community settings. They bring ground-level implementation knowledge from South Asia — real-world patient populations, healthcare access constraints, and socio-economic context — that enriches large European research programs. Their contributions are applied rather than laboratory-based, focused on how health interventions are adopted and scaled in diverse, resource-limited environments.

What they specialise in

How they've shifted over time

Their earliest H2020 involvement (INDIGO, from 2020) was anchored in biomedical vaccine technology — adjuvants, recombinant antigens, microneedle delivery systems — suggesting initial engagement through laboratory-adjacent clinical or translational work. Their more recent projects pivoted sharply toward public health infrastructure: pandemic cohort coordination, federated data analysis, cervical cancer community screening, and AI-assisted protocol uptake in underserved populations. The trend is a clear shift from the science of vaccines toward the science of health system delivery, particularly in fragile and low-resource contexts.

CBCI is moving toward digital and AI-assisted public health delivery in low-resource settings — making them a relevant partner for projects bridging European health technology with South Asian or Global South implementation contexts.

How they like to work

CBCI has not led any H2020 projects as coordinator; all three participations are as a partner or international third party, consistent with a specialist contributor role rather than a project driver. They operate within large consortia — 64 unique partners across 19 countries — suggesting they are brought in to provide specific geographic, clinical, or community-access expertise rather than to manage the project overall. This makes them a reliable addition for consortia needing real-world health implementation data from India or similar settings.

CBCI has engaged with 64 unique consortium partners across 19 countries, a notably broad network for an organization with only 3 projects — reflecting participation in large, multi-country health consortia. Their geographic footprint spans Europe and at least South Asia, given their India base and international partner classification in two projects.

What sets them apart

CBCI's distinctive value is their position as an India-based medical education and community health institution embedded in European research consortia — they provide access to patient populations, healthcare delivery realities, and socio-economic contexts that European partners cannot replicate internally. For projects requiring non-European real-world evidence, especially in preventive health, infectious disease, or cancer screening, CBCI bridges the gap between lab-developed interventions and field implementation. Their involvement in both a long-running vaccine platform project (INDIGO, 2020–2026) and a cervical cancer elimination initiative signals sustained commitment to global health equity research.

Highlights from their portfolio

• INDIGO
  A 2020–2026 flagship project developing affordable, needle-free influenza vaccines with microneedle patch delivery — CBCI's longest engagement and most technically specific role.
• ORCHESTRA
  A large pan-European COVID-19 cohort study using federated learning and statistical modeling across fragile populations, with CBCI contributing low-resource setting expertise.
• PRESCRIP-TEC
  Targets cervical cancer elimination through AI-assisted community screening — notable for combining artificial intelligence with grassroots public health implementation.